Search Browse Earnings

Entrada Therapeutics, Inc. — SlamSEC

Entrada Therapeutics, Inc.

Nasdaq:TRDA

Pharmaceutical Preparations·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$210.8M

+63.4% YoY

FY 2025

Adj. EBITDA

$50.8M

24.1% margin

FY 2025

Net Income

$65.6M

31.1% margin

FY 2025

EPS (Diluted)

$1.68

FY 2025

Stock Price

$13.21

+5.3%

2026-03-10

52W Range

$4.93 – $13.10

P/E Ratio

7.9x

Market Cap

$505.7M

Cash

$101.2M

FY 2025

Total Debt

—

Net Cash

$101.2M

FY 2025

Enterprise Value

$404.5M

Debt / EBITDA

-2.0x

FY 2025

EV / EBITDA

8.0x

Employees

—

CEO

Doshi Dipal

CFO

Wentworth Kory James